News

Peter O'Donnell writes about the results of a public opinion survey, the latest the European drug industry's attempts to fight back against what it sees as a climate of misunderstanding.

Tony Fiorino, Chief Medical Officer of electroCore, discusses challenges he has faced with device studies, and will elaborate on his experiences about the differences between device and drug trials.

How to account and adjust for covariates in clinical trial randomization-and be confident about uncertainty.

A trial’s success depends on enrolling the planned number of patients in the shortest possible time frame. Such thinking can insight a limited focus on obtaining and analyzing all investigator site enrollment data - as if that would solve all problems pertaining to site enrollment performance, writes Gen Li, President of Phesi.

Cathleen Dohrn, Senior Scientific Director for Continuum Clinical, describes the momentous challenges in clinical trials presented by low awareness of nonalcoholic steatohepatitis.

A look at three contemporary trends that though integrated cautiously at first, may open up a reimagined world of clinical research.

Penelope Manasco, CEO of MANA UBM, answer thorny questions about adopting electronic investigator site files in clinical research.

Bill Tobia, CEO of Clinstruct, Ahmed Bouzid, CEO, Witlingo, and Brielle Nickoloff, Lead Product Marketing, Witlingo, discuss how voice will change the clinical research paradigm.

Penelope Manasco, CEO of MANA UBM, disputes recommendations made by the original authors she finds to be problematic and worthy of further discussion.

David M. Kronfeld, the Head of Real World Data Innovation for Medidata, writes of Mercy Hospital in Joplin, Missouri, that despite seeing over 600 new cancer patients each year, it has historically had very limited access to clinical trials